Kornimate/medical-research-clean huggingface dataset:
discovering urinary protein biomarkers for hepatocellular carcinoma in chronic hepatitis b population

Conditions: Hepatocellular Carcinoma; Hepatitis B

Summary: chronic hepatitis b (chb) can lead to hepatocellular carcinoma (hcc), imposing a significant health and economic burden globally. early detection of hepatitis b virus-related hcc (hbv-hcc) in chb with potential biomarkers has become a pressing and difficult challenge. recent advancements in urinary proteomics offer a promising approach for hbv-hcc biomarker identification, utilizing liquid chromatography with tandem mass spectrometry for urine proteome analysis. differential analysis using limma in r software will uncover upregulated proteins in hbv-hcc.


Eligibility criteria:
inclusion criteria: 1. age \> 18 years old; 2. previously healthy individuals without underlying diseases, confirmed to be free of hepatitis b infection through hbv serum markers, with regular physical examinations and blood biochemistry tests; 3. chronic hepatitis b patients diagnosed through hbv serum markers, alpha-fetoprotein (afp) concentration, clinical features, or imaging examinations; 4. hepatitis b-related liver cancer patients with complete clinical data, preoperatively tested positive for hbsag, diagnosed based on clinical features and imaging examinations preoperatively, and pathologically confirmed with hcc postoperatively; 5. patients with non-hepatocellular liver cancer, preoperatively diagnosed based on clinical features and imaging examinations, with negative hbsag, and pathologically or by biopsy confirmed as non-hepatocellular liver cancer without liver metastasis, with complete clinical data and no liver metastasis; 6. able to independently sign an informed consent form. exclusion criteria: 1. patients with long-term heavy alcohol consumption; 2. patients with chronic hepatitis c infection; 3. patients with autoimmune diseases; 4. patients who have taken drugs known to have definite hepatotoxicity within the past year; 5. patients with urinary system infections; 6. patients with hematuria; 7. patients with significant proteinuria; 8. patients with tumors of the urinary system; 9. patients with acute infectious diseases; 10. patients with hepatitis b-related liver cancer who also have tumors other than primary hepatocellular carcinoma.
zoledronic acid combined radiotherapy for bone metastasis of non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer; Bone Metastasis

Summary: this study will give comparison of the bone pain remission and the adverse reaction of zoledronic acid combine with high dose fractionation radiotherapy(30gy/10f) and zoledronic acid combine with low dose fractionation radiotherapy(15gy/5f) . the purpose of this trial is to prove whether zoledronic acid combine radiotherapy can reduce radiotherapy dose in treatment of non-small cell lung cancer bone metastasis'pain relief or not.

further study details as provided by oncology center of daping hospital

Eligibility criteria:
inclusion criteria: * pathology or cytology was diagnosed with non-small cell lung cancer, and bone metastases was confirmed by ct or mri , and the patients have to need intervention treatment. * vas score\>2 points. * no paraplegia, * no pathological fractures of bone related events which require surgical intervention, * no major organ dysfunction,laboratory indexes meet the following requirements: haemamoeba \>4.0 x 10\^9/l, neutrophile granulocyte \> 2 x 10\^9/l, the platelet count\>100 x 10\^9/l, hemoglobin\>100 g/l; liver result: the serum bilirubin is lower than normal ceiling; alt and ast is lower than the maximum normal 1.5 times; cr\ 60 ml/min. exclusion criteria: * the patients who have allergy of bisphosphonates and zoledronate. * the patients who receive molecular targeted therapy and chemotherapy within one month，the patients who receive calcitonin and aminoglycoside therapy in one week. * the patients who receive pamidronic acid in 28 days，the patients original sites receive radiotherapy before. * the patients who have history of thyroid surgery，receive tooth extraction in 2 weeks，and have been suffered from bone fracture and paraplegia. * the patients who have serious internal medicine diseases and acute infection. * the patients with a history of psychiatric * pregnancy or breast-feeding women, men have fertility requirements * patients within clinical trials or not more than 30 days

Keywords: zoledronic acid radiotherapy
personalizing treatment delivery

Conditions: Anxiety Disorders and Symptoms; PTSD and Trauma-related Symptoms; Alcohol; Use, Problem; Alcohol Use Disorder

Summary: anxiety and anxiety-related disorders frequently co-occur with alcohol use problems resulting in an enormous humanitarian and economic cost to society. the proposed research will use digital technology to examine person-specific risk factors predicting problematic alcohol use in individuals vulnerable to anxiety and anxiety-related disorders and will use this information to design a personalized intervention for individuals seeking psychological treatment. results from this research will integrate output from novel and innovative digital technology methods into psychotherapy, advancing research on personalized treatment and prevention efforts.


Eligibility criteria:
inclusion criteria: * access to a smart phone * between 18 and 65 years * clinically significant anxiety or trauma-related symptoms * alcohol use problems * interest in telehealth counseling * anticipated new jersey or new york residence for the duration of the study exclusion criteria: * currently receiving counseling * psychiatric medication that is not currently at a stable dose (or is not anticipated to remain at a stable dose for the duration of the study) * demonstrated indicators of more intensive or acute care * temporary residence within the state of new jersey or new york or out-of-state residence from the state of new jersey or new york
comparison between laparoscopic common bile duct exploration and intraoperative ercp for management of common bile duct stones

Conditions: Common Bile Duct Gallstones

Summary: many options are available for management of common bile duct stones. the most recent development in this field is single-session approach by one of two methods; laparoscopic common bile duct exploration and intraoperative endoscopic sphincterotomy. in this study, the investigators prospectively compare these two methods for management of patients with preoperatively diagnosed common bile duct stones to settle the best option.


Eligibility criteria:
inclusion criteria: * preoperatively diagnosed common bile duct stones exclusion criteria: * liver cirrhosis pregnancy asa iii, iv previous abdominal surgery postcholecystectomy

Keywords: common bile duct stones laparoscopic common bile duct exploration intraoperative ercp preoperatively diagnosed common bile duct stones
study of gs-1427 in participants with moderately to severely active ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the goal of this study is to learn if gs-1427 is effective in treating participants with moderate to severe ulcerative colitis. the study will compare participants in different treatment groups treated with gs-1427 with participants treated with placebo. the primary objective of this study is to assess the efficacy of gs-1427, compared with placebo control, in achieving clinical response at week 12.


Eligibility criteria:
key inclusion criteria: * individuals have ulcerative colitis (uc) with symptoms of at least 90 days duration before randomization, with the diagnosis confirmed by endoscopy and histology at any time prior to randomization. documentation of endoscopy and histology consistent with the diagnosis of uc must be available in the source documents. * individuals have uc with minimum disease extent of 15 cm from the anal verge. * individuals have moderately to severely active uc as determined by endoscopy occurring during screening with a total modified mayo clinic score (mmcs) of 5 to 9 points, including a centrally read endoscopic subscore of at least 2. * individuals have an inadequate response or loss of response or are intolerant to at least 1 of the following uc treatments: corticosteroids, immunomodulators, or advanced therapy. * individuals have an inadequate response or loss of response or are intolerant to \< 3 at mechanisms of action for uc (use of 2 or more at with the same mechanism of action, eg, 2 tnf-α inhibitors, counts as 1 mechanism of action) key exclusion criteria: * have a current diagnosis of crohn's disease (cd) or clinical findings suggestive of cd, diagnosis of indeterminate colitis due to etiologies such as an enteric pathogen, or lymphocytic or collagenous colitis. * have a current diagnosis of toxic megacolon, symptomatic colonic stricture, acute severe colitis, fulminant colitis, or abdominal abscess at screening or randomization. * have any history of exposure to vedolizumab or other integrin antagonists * requirement for ongoing therapy with or use of any prohibited medication as specified in the protocol note: other protocol defined inclusion/exclusion criteria may apply
a study to compare the efficacy, safety, immunogenicity, and pharmacokinetic profile of hlx17 vs. keytruda® in the first-line treatment of advanced non-squamous non-small cell lung cancer

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Summary: this is a multicentre, randomized, double-blind, parallel-controlled integrated phase i/iii clinical study to evaluate the similarity in efficacy, safety, pk profile, and immunogenicity of hlx17 vs. keytruda®( us- and eu-sourced) in the first-line treatment of advanced non-squamous non-small cell lung cancer.

this study includes three treatment groups. patients will be randomly assigned at a 2:1:1 ratio to the hlx17, us-sourced keytruda® and eu-sourced keytruda® group to receive the treatment of imps in combination with carboplatin plus pemetrexed until disease progression, initiation of new anti-tumor therapy, withdrawal of informed consent form, death, unacceptable toxicity, or up to 17 cycles (whichever occurs first).

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of stage iv inoperable to surgery or radiotherapy (ajcc 8th edition) non-squamous nsclc. * without any tumor activating egfr mutation or alk or ros1 gene rearrangement. * have not received prior systemic treatment for their advanced/metastatic nsclc. * at least one measurable lesion as assessed by irrc based on recist v1.1. * have a performance status of 0 or 1 on the eastern cooperative oncology group (ecog) performance status. * have adequate organ function. exclusion criteria: * subjects with nsclc of other histopathological types, such as mixed adenosquamous carcinoma, and subjects with small cell lung cancer or neuroendocrine carcinoma. * subjects with other active malignancies within 5 years or at the same time prior to screening. * active central nervous system metastases. * known interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, and severe lung function abnormalities that may impede the investigators' diagnosis and management of drug-related pulmonary toxicity. * known active or suspected autoimmune diseases. * history of immunodeficiency, including hiv antibody positive, active hepatitis b; or hepatitis c virus infections. * have received pembrolizumab or any other immune checkpoints inhibitors (pd-1, pd-l1, ctla4, etc.) before screening. * pregnant or breastfeeding female. * the investigator has a clear reason to believe that participation in this study would be detrimental to the subject.

Keywords: keytruda biosimilar
gingivitis and periodontitis as a risk factor for stroke

Conditions: Gingivitis; Periodontitis; Stroke

Summary: periodontitis and gingivitis are one of the most infectious diseases in humans. several studies have been carried out on the dependence of periodontitis and stroke. the aim of this study was to investigate gingivitis and periodontitis as risk factors for stroke in the pakistani population.

epidemiologic studies have shown that cerebrovascular accident (cva) is the 3rd cause of death in developed countries with 0.8 % prevalence in the whole population. although, the prevalence rate of stroke is reduced yet is one of the most important health problems in the united state. periodontitis and gingivitis are the two most infectious man diseases. today, it is estimated that about 35% of people over 30-year-old in america and 50-55% of people in developing countries are involved with these diseases. these diseases are due to the practice of chronic bacterial infection and the inflammatory response of the host. the relationship between periodontitis and cva was first introduced by mackenzi and millard in 1963 but the importance of this issue was not understood. periodontal infection can be a complex multiphase disease by associating this infection with organ systems such as cardiovascular, endocrine, reproductive, and respiratory systems. nowadays, periodontitis is considered a risk factor for atherosclerosis and thromboembolic disease.

Eligibility criteria:
inclusion criteria: * diagnosed stroke by using brain imaging from magnetic resonance imaging and/or computerized tomography. exclusion criteria: * not willing to participate * neurological complications other than stroke
search for phenotype-modifying genes in patients with intellectual disabilities.

Conditions: Intellectual Disability

Summary: each form of intellectual disability under study is a rare disease in its own right, and it is therefore difficult to study the variability of its expression. it therefore appears necessary to study large series of patients with intellectual disabilities. the objective is to identify variants in phenotype-modifying genes in patients with intellectual disability.

thanks to the contribution of ngs analyses (exome and genome analysis), the rate of etiological diagnosis in intellectual disability is currently approaching 42% in some meta-analyses. at bordeaux university hospital, since 2017, 700 patients have been sequenced for intellectual disability, with a diagnostic rate of 33%. in genetics, epistasis refers to the interaction between two or more genes. as part of its previous work, bionomeex has developed an algorithm called gwas-2d (genome wide association study 2 dimension) which makes it possible to observe, from a large number of samples and for a given phenotype, the relationships existing between two loci on the genome. the gwas-2di project involves the reanalysis of exome sequencing data from patients with intellectual disabilities at bordeaux university hospital, using a gwas-2d algorithm developed by bionomeex to search for phenotype-modifying genes.

Eligibility criteria:
inclusion criteria: * patients with intellectual disability or related but not affected by them * major or minor with autorisation of legal representative * exome sequencing in bordeaux university hospital between 2018 and 2024 exclusion criteria: * refusal to participate in research protocols * refusal to participate expressed following receipt of information letter.

Keywords: intellectual disability epistatic interaction
the efficacy of phosphatidylserine-omega3 in elderly subjects with memory impairment

Conditions: Memory Impairment

Summary: the primary objective of this trial is to assess the ability of phosphatidylserine-omega3 to improve cognitive performance in elderly subjects with memory impairment. this study is a single-center, open-label 15 weeks duration trial to assess efficacy of phosphatidylserine-omega3 in elderly subjects with memory impairment.


Eligibility criteria:
inclusion criteria 1. ability to give written informed consent 2. age: 90≥ years ≥65 3. gender: male and female. 4. clinical dementia rating scale (cdr) ≤ 0.5 5. mini-mental state examination (mmse) ≥ 26 6. memory test performance within or below the mean established for adults, with maximum of four neuropsychological subtests of the computerized test scored as 1.5 sd above the mean 7. language: subjects must be able to read, write and speak hebrew. 8. ability to perform tests and interviews. exclusion criteria 1. evidence of delirium, confusion, or other disturbances of consciousness. 2. any neurological disorder that could produce cognitive deterioration. such disorders include ad, parkinson's disease, stroke, intracranial hemorrhage, local brain lesions including tumors, and normal pressure hydrocephalus 3. history of any infective or inflammatory brain disease including those of viral, fungal, or syphilitic etiologies. 4. head injury immediately preceding cognitive deterioration. 5. current psychiatric diagnosis according to dsm iv criteria of depression, mania, or any other major psychiatric disorder, or evidence of depression as determined by the geriatric depression scale (gds15) score of 5 or more. 6. current diagnosis or history of alcoholism or drug dependence. 7. any medical disorder that could produce cognitive deterioration including renal, respiratory, cardiac and hepatic disease, diabetes mellitus, endocrine, metabolic or hematological disturbances unless well controlled, and malignancy not in remission for more than two years. 8. use of psychotropic drug or any other drug or supplement that may significantly affect cognitive functioning during the month prior to psychometric testing. 9. use of any experimental medication within 1 month prior to screening or as concomitant medications. 10. history of hypersensitivity or allergy to fish or fish oil.

Keywords: age associated memory impairment
short term outcomes after proton and photon radiotherapy for idh mutated grade 2 and 3 gliomas

Conditions: Glioma; Radiotherapy; Complications

Summary: rationale: proton beam therapy has recently become available for the treatment of patients with who grade 2 and 3 idh mutated (idhmt) glioma in the netherlands. the dose distributions associated with proton therapy have substantially reduced the volume of the normal brain irradiated with low and intermediate radiotherapy doses. whether this impacts rates of progressive disease or safety issues and how this compares with a similar population treated with photon therapy is currently unknown. objective: to investigate short term outcomes after proton and photon radiotherapy for grade 2 and 3 idhmt glioma.

patients with grade 2 and 3 idhmt glioma treated with proton therapy in holland ptc, maastro and umc groningen and referred erasmus mc, haaglanden mc, lumc, amsterdam umc, verbeeten institute, maastro, umc groningen, and leuven university hospital between 1st of january 2018 and the 30th of june 2022. the outcomes will be compared to those from patients with grade 2 and 3 idhmt glioma treated with photon therapy in the same institutes and during the same period of time. the applied clinical target volume (ctv) margins and the chemotherapy are preferably similar for proton and photon therapy. retrospective data will be collected from the electronic records of each participating institute. for the primary outcome, data will be collected on interventions (radiotherapy, surgery, chemotherapy, medication) for either tumor progression or toxicity after radiotherapy. this will be used to calculate next intervention free survival as primary outcome. for the secondary outcomes, data on survival, disease progression, pseudoprogression, and toxicity will be used to calculate overall survival, progression free survival, and pseudoprogression free survival, as well as toxicity incidence.

Eligibility criteria:
inclusion criteria: * histopathologically confirmed who grade 2 or grade who 3 idhmt glioma * treatment with radiotherapy delivered between 1 of january 2018 and completed before or on the 30th of june 2022 * treatment with chemotherapy delivered after radiotherapy (pcv or temozolomide) * age ≥ 18 years exclusion criteria: * prior cranial radiotherapy * contra-indication for mri imaging * chemotherapy delivered before radiotherapy * dose and fractionation other that standard dose (50.4 gy in 28 fractions for grade 2 and 59.5 gy in 33 fractions for grade 3) * combination photon and proton therapy * patient has previously opted-out of the use of their data for research

Keywords: neuro-oncology proton therapy photon therapy
deprescribing and health-related effects

Conditions: Chronic Disease

Summary: in a primary care settled quality improvement project aiming to deprescribe medication through a medication review intervention, we investigated how the implemented medication changes affected health-related outcomes in real-life patients.

the project was approved by the management in the municipality of frederikshavn. according to danish legislation, no formal permission from the national or regional committee on health research ethics was required for this type of study, as patients were not treated inferior to usual care and no biological material was collected. it was conducted as a quality improvement project and informed consent was not required for the specific data collected. the study is in compliance with the general data protection regulation and a part of north denmark region's record of processing activities (k2023-008).

Eligibility criteria:
inclusion criteria: * new residents and residents that had not yet attended a consultation focusing on pharmacological treatment in the chronic care model. * patients were invited for the consultation focusing on pharmacological treatment in the month of their birthday and, thereby, included randomly and consecutively throughout the study period. exclusion criteria: * unable to collaborate on follow-up questionnaires

Keywords: primary care medication review deprescribing polypharmacy chronic disease management
effect of n-acetyl cysteine and zinc in management of head and neck cancer radiotherapy induced oral mucositis

Conditions: Radiation-Induced Mucositis

Summary: the majority of individuals diagnosed with head and neck cancer, who undergo radiotherapy or concurrent chemoradiotherapy, experience oral mucositis. our research focuses on investigating the preventive and therapeutic impact of n-acetylcysteine and zinc in managing radiotherapy-induced oral mucositis.

almost all head and neck cancer patients who to receive radiotherapy or concurrent chemotherapy suffer from oral mucositis. oral mucositis (om) is associated with pain, difficulty in eating, dysphagia, and the need for enteral or parenteral nutrition, increased opioid consumption or even interruptions to cancer therapy. in immunosuppressed patients, om is associated with bacteremia, increased inpatient hospitalization duration and higher 100-day mortality. treatments to manage cancer, such as radiotherapy, generates reactive oxygen species (ros) that target neoplastic cell dna resulting in cell damage and death. ros from these therapies also indiscriminately target healthy non-neoplastic dna. zinc carries out its antioxidant function in two ways: reducing the concentration of oxidant agents and protecting structures and macromolecules suffer from oxidant agent. n-acetylcysteine is an aminothiol and precursor to glutathione (gsh), glutathione in its reduced form is the most powerful intracellular antioxidant, thereby protecting against radiation-induced free radical damage. our study is a randomized, controlled, parallel clinical trial that will be applied at clinical oncology and nuclear medicine center at mansoura university hospital to investigate the prophylactic and therapeutic effect of n-acetylcysteine and zinc on radiotherapy induced oral mucositis in head and neck cancer patients.

Eligibility criteria:
eligibility criteria inclusion criteria: * patients aged 18 years or older. * patients diagnosed with head and neck cancer. * patients are recommended for treatment with radiotherapy with a minimum dose of 20 gy. exclusion criteria: * pregnancy and lactating women. * cigarette smoker patients. * patients with severe comorbid illnesses or immunocompromised status. * patients receiving induction chemotherapy or those with previous head and neck radiotherapy. patients using amifostine during radiotherapy.